(Q33385774)

26 July 2017

title

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy (English)

1 reference

26 July 2017

1 reference

Michelle Shayne

1

1 reference

26 July 2017

Eva Culakova

2

1 reference

26 July 2017

Debra Wolff

3

1 reference

26 July 2017

Marek S Poniewierski

4

1 reference

26 July 2017

David C Dale

5

1 reference

26 July 2017

Jeffrey Crawford

6

1 reference

26 July 2017

Gary H Lyman

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

115

1 reference

26 July 2017

issue

22

1 reference

26 July 2017

page(s)

5319-5328

1 reference

Aging and cancer in America. Demographic and epidemiologic perspectives

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Simplified calculation of body-surface area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Epidemiology of hypertension in African American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Breast cancer treatment of older women in integrated health care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Trends in acute myocardial infarction and coronary heart disease death in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24560

7 January 2021

Identifiers

DOI

10.1002/CNCR.24560

1 reference

26 July 2017

1 reference